PARIS (Reuters) - French drug maker Sanofi will announce the price of the potential COVID-19 vaccine it is developing with Britain’s GlaxoSmithKline after it has released Phase I/II results of the trials, vaccines chief Thomas Triomphe said on Thursday.
The company is expected to release the results from the Phase I/II clinical trials this month.
It is also developing a vaccine with U.S. biotech firm Translate Bio, with clinical human trials expected to start this month.
Reporting by Matthias Blamont in Paris; Writing by Josephine Mason in London; Editing by Jon Boyle
Our Standards: The Thomson Reuters Trust Principles.